NKF: Subsidiary Meitheal Pharmaceuticals Inc. received new drug injection registration approval from the U.S. FDA for phosphomycin
NKF announced that its subsidiary Meitheal Pharmaceuticals Inc. has received a new drug approval letter from the U.S. Food and Drug Administration for injectable fosfomycin, 6g/bottle. The company has invested approximately 47.211 million yuan in research and development expenses. The newly approved product will be arranged for sale in the United States in the near future, which is expected to have a positive impact on the company's operating performance